Exposure‐response relationships for the efficacy and safety of filgotinib and its metabolite GS‐829845 in subjects with rheumatoid arthritis based on phase 2 and phase 3 studies

AIMS: Filgotinib is a potent, oral, JAK1‐preferential inhibitor for the treatment of rheumatoid arthritis (RA). This report describes exposure‐response (ER) analyses of filgotinib for dose confirmation based on three phase 3 and two phase 2 studies in moderate to severe RA patients. METHODS: The pha...

Descripción completa

Detalles Bibliográficos
Autores principales: Meng, Amy, Anderson, Kacey, Nelson, Cara, Ni, Liyun, Chuang, Shu‐Min, Bellanti, Francesco, Chang, Peter, Comisar, Craig, Kearney, Brian P., Bartok, Beatrix, Mathias, Anita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305466/
https://www.ncbi.nlm.nih.gov/pubmed/35072287
http://dx.doi.org/10.1111/bcp.15239

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305466/
https://www.ncbi.nlm.nih.gov/pubmed/35072287
http://dx.doi.org/10.1111/bcp.15239

Ejemplares similares